

RECEIVED
CENTRAL FAX CENTER

001/007

SEP 28 2007

J.C. PATENTS
 4 VENTURE, SUITE 250
 IRVINE, CALIFORNIA 92618
 TEL.: (949) 660-0761
 FAX: (949) 660-0809
 E-MAIL: jcp1@email.msn.com

CERTIFICATE OF TRANSMISSION

September 28, 2007

Atty Docket No. :	JCLA14660-R
Appl. No. :	10/511,018
Filing Date :	March, 14, 2005
Pages :	Cover + 6

BY FACSIMILE ONLY

Fax No. :	571-273-8300
Attention :	EXAMINER : CLARK, AMY LYNN
Group Unit :	1655
From :	Jiawei Huang, Reg. No. 43,330
MESSAGE :	Enclosed herewith is a Response to Restriction in 6 pages.

Sir:

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office on September 28, 2007 at the above indicated fax number.

Sign by:

Michelle Chang

Note: This facsimile transmission is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this transmission in error, please kindly notify us immediately, and return the original message to us at the above address. We greatly appreciate your cooperation.

RECEIVED
CENTRAL FAX CENTER

Z002/007

SEP 28 2007

PATENT

Docket No.: JCLA14660-R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Applicant : TETSUO SANTO et al.
Application No. : 10/511,018
Filed : March 14,2005
For : CREAM FOR THERAPY OF DERMATITIS
Art Unit : 1655
Examiner : CLARK, AMY LYNN

RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed on August 29, 2007 regarding the above-identified application, Applicant elects Specie C, claims 11 and 15, for further examination on merits. Claims 9, 10, and 12 are generic and should be examined together with the elected species. Please withdraw claims 13, 14 and 16.